Sumitomo Dainippon Pharma to Participate in Global Partnership "Access Accelerated" to Address Non-Communicable Diseases
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; "Sumitomo Dainippon Pharma") announced today that it participates in "Access Accelerated" the world's first global partnership to advance access to non-communicable disease (NCD) prevention, treatment, and care through partnerships among global pharmaceutical companies.
Twenty-two global pharmaceutical companies launched Access Accelerated, delivered in partnership with the World Bank Group and the Union for International Cancer Control (UICC), is focused on improving access to prevention, treatment, and care of NCDs, such as cancers and cardiovascular diseases, in low and lower-middle income countries where nearly 80 percent of NCD-related deaths occur. Its goal is to work towards the United Nations (UN) Sustainable Development Goal (SDGs) target to reduce premature deaths from NCDs by one-third by 2030. Its launch was announced today at the World Economic Forum held in Davos, Switzerland.
Masayo Tada, Representative Director, President and CEO of Sumitomo Dainippon Pharma, stated that "SDG 3: Ensure healthy lives and promote well-being for all at all ages" is one of the SDGs of the UN, an ambitious goal for one pharmaceutical company to undertake alone. With the commitment of 22 companies, I believe we can take a big step forward toward good health and well-being. To achieve this together and individually, Sumitomo Dainippon Pharma contributes to improving access to healthcare as one of the members of the global pharmaceutical industry. We do this through the continuous creation of innovative pharmaceutical products in the areas of Psychiatry & Neurology and Oncology, which have been designated as the focus therapeutic areas.
Sumitomo Dainippon Pharma will remain committed to advancing access to healthcare in developing countries to make continued contributions to global health.
Non-Communicable Diseases (NCDs)
NCDs, including cancers, cardiovascular diseases, chronic respiratory disease, diabetes and mental health disorders are the leading causes of death and disability worldwide. This places a double burden on communities and economies around the world already combating infectious diseases.
Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving NCD care. Involving more than 20 biopharmaceutical companies, the initiative works with partners such as World Bank Group and the Union for International Cancer Control (UICC) to help overcome a variety of access barriers to NCD medicines in low-income and lower-middle income countries. Access Accelerated will support multi-stakeholder dialogue and begin on-the-ground work to improve NCD prevention, diagnosis and treatment. For more information, please visit http://www.accessaccelerated.org.